TGT
Target Teams With Warby Parker for in-Store Eyewear Shopping
Target is opening a series of “shop-in-shops” in partnership with eyewear maker Warby Parker. The collaboration, announced Thursday (Feb. 27), will bring five “Warby...
Read moreDetails
Occidental Petroleum Hit Its $4.5 Billion Debt Reduction Target 7 Months Early. That’s Paying Big Dividends for Investors.
Occidental Petroleum (OXY -3.21%) unveiled a very bold move at the end of 2023. The oil producer agreed to buy...
Read moreDetails
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Target Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – TGT
NEW YORK, Feb. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of...
Read moreDetails
This 6%-Yielding Dividend Stock Hits Its Target for the 19th Year in a Row
Enbridge (ENB -3.83%) operates a very predictable business. Its pipeline and utility assets generate very stable cash flow backed by...
Read moreDetails
First Trust Lists 3 New Target Income ETFs
Today, First Trust Advisors announced it is expanding its roster of Target Income ETFs with the launch of three new...
Read moreDetails
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Target and Monolithic Power Systems and Encourages Investors to Contact the Firm
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm,...
Read moreDetails
2 Excellent S&P 500 Dividend Stocks to Buy in January
The bull market has sent the S&P 500 up 23% over the last year. But this run has brought the...
Read moreDetails
Is Trending Stock Target Corporation (TGT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Target (TGT). This makes it worthwhile to examine what the stock...
Read moreDetails
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
SAN FRANCISCO , Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment...
Read moreDetails
Target (TGT) Stock Sinks As Market Gains: Here’s Why
The latest trading day saw Target (TGT) settling at $138.22, representing a -0.74% change from its previous close.
Read moreDetails